Inhibition of P-glycoprotein (ABCB1)- and multidrug resistance-associated protein 1 (ABCC1)-mediated transport by the orally administered inhibitor, CBT-1((R)).
about
Tetrandrine, a Chinese plant-derived alkaloid, is a potential candidate for cancer chemotherapyA high throughput flow cytometric assay platform targeting transporter inhibitionA combination of curcumin with either gramicidin or ouabain selectively kills cells that express the multidrug resistance-linked ABCG2 transporterA pharmacodynamic study of docetaxel in combination with the P-glycoprotein antagonist tariquidar (XR9576) in patients with lung, ovarian, and cervical cancer.Rapid detection of ABC transporter interaction: potential utility in pharmacology.Combining small molecules for cell reprogramming through an interatomic analysis.Very important pharmacogene summary: ABCB1 (MDR1, P-glycoprotein)NVP-TAE684 reverses multidrug resistance (MDR) in human osteosarcoma by inhibiting P-glycoprotein (PGP1) function.Antitumor agents. 293. Nontoxic dimethyl-4,4'-dimethoxy-5,6,5',6'-dimethylenedioxybiphenyl-2,2'-dicarboxylate (DDB) analogues chemosensitize multidrug-resistant cancer cells to clinical anticancer drugs.Improving cancer chemotherapy with modulators of ABC drug transporters.Crizotinib (PF-02341066) reverses multidrug resistance in cancer cells by inhibiting the function of P-glycoproteinDiscovery and preliminary SAR of bisbenzylisoquinoline alkaloids as inducers of C/EBPαSaracatinib (AZD0530) is a potent modulator of ABCB1-mediated multidrug resistance in vitro and in vivo4-Isoxazolyl-1,4-dihydropyridines exhibit binding at the multidrug-resistance transporterCetuximab enhanced the efficacy of chemotherapeutic agent in ABCB1/P-glycoprotein-overexpressing cancer cells.Effect of ceritinib (LDK378) on enhancement of chemotherapeutic agents in ABCB1 and ABCG2 overexpressing cells in vitro and in vivo.Regression of prostate cancer xenografts by RLIP76 depletion.Preclinical validation of Aurora kinases-targeting drugs in osteosarcoma.The expression and significance of P-glycoprotein, lung resistance protein and multidrug resistance-associated protein in gastric cancerUMMS-4 enhanced sensitivity of chemotherapeutic agents to ABCB1-overexpressing cells via inhibiting function of ABCB1 transporter.Novel 5-oxo-hexahydroquinoline derivatives: design, synthesis, in vitro P-glycoprotein-mediated multidrug resistance reversal profile and molecular dynamics simulation study.Alectinib (CH5424802) antagonizes ABCB1- and ABCG2-mediated multidrug resistance in vitro, in vivo and ex vivoInteractions of dietary phytochemicals with ABC transporters: possible implications for drug disposition and multidrug resistance in cancer.RLIP76 Targeted Therapy for Kidney CancerNovel and emerging strategies in drug delivery for overcoming the blood-brain barrier.The controversial role of ABC transporters in clinical oncology.Reversal of ATP-binding cassette drug transporter activity to modulate chemoresistance: why has it failed to provide clinical benefit?The ability of molecular docking to unravel the controversy and challenges related to P-glycoprotein--a well-known, yet poorly understood drug transporter.Nanodrug delivery in reversing multidrug resistance in cancer cells.Oral antineoplastic agent interactions with medicinal plants and food: an issue to take into account.Targeting polo-like kinase 1 by NMS-P937 in osteosarcoma cell lines inhibits tumor cell growth and partially overcomes drug resistance.Tivozanib reverses multidrug resistance mediated by ABCB1 (P-glycoprotein) and ABCG2 (BCRP).PD173074, a selective FGFR inhibitor, reverses ABCB1-mediated drug resistance in cancer cells.Combined use of anticancer drugs and an inhibitor of multiple drug resistance-associated protein-1 increases sensitivity and decreases survival of glioblastoma multiforme cells in vitro.Cancer resistance to treatment and antiresistance tools offered by multimodal multifunctional nanoparticles.Dacomitinib potentiates the efficacy of conventional chemotherapeutic agents via inhibiting the drug efflux function of ABCG2 in vitro and in vivo.Palladium-catalyzed oxidative carbamoylation of isoquinoline N-oxides with formylamides by means of dual C-H oxidative coupling.Dimeric isoxazolyl-1,4-dihydropyridines have enhanced binding at the multi-drug resistance transporter.2-Trifluoromethyl-2-Hydroxypropionamide Derivatives as Novel Reversal Agents of ABCG2 (BCRP)-Mediated Multidrug Resistance: Synthesis and Biological Evaluations.Synthesis and biological evaluation of indole-based UC-112 analogs as potent and selective survivin inhibitors.
P2860
Q26749391-EC8C5D5E-815A-4DEB-819C-C1B253FEDF67Q33912745-8A8F083C-10F2-45AC-BFF9-602CFBA235FDQ34467622-E3C04B5E-78BA-4362-A391-10994D22D13DQ34768677-623CC897-F636-4D72-8223-CBC0F3BBD59BQ34913068-FB76D716-2508-40D6-99A4-FA407BAF2340Q34993880-380AE6D6-DA9F-40E0-A5A3-64D753915E6DQ34994901-4F579F1A-07FB-485E-84C1-3E19CA81D43BQ35851832-53577828-25B0-4F38-B9BA-07979EB42E9AQ36032565-018E93AF-1B79-4CF3-A45B-5A5C959929D9Q36108251-A3B4958F-43A0-4355-AEAD-ECA7F7869071Q36166672-92C7D5AC-2A96-49BA-B34F-3653E9A7B227Q36196811-B1993AB2-5AAF-486F-A6A1-0931BB000F65Q36282183-A7D91BF8-4C78-4589-B25C-B3254CC8C243Q36341893-AE2CE9B3-C136-4C9C-A629-BFC6A149BF29Q36562186-647172F7-39EE-4F2A-BCC2-003B88CE4654Q36689070-D3ECFF65-83FB-45BE-A291-94AAE04999CCQ37194622-ABBB56E1-843B-4D85-9EC6-3484461545DCQ37323073-21852855-4997-49BD-B7EC-E96B8AE43F4EQ37458683-70EFCDC1-6AFF-4030-88B2-EE96E6D69517Q37650134-47DBD1B4-79F1-49A2-9DB8-4B1ECBB5995BQ37652854-CF5DC6E9-4A08-49AD-99FD-20D5454C918FQ37739472-78BE2762-4A55-405D-96B8-48E5947C1BDBQ37740126-CFBF86F3-79A5-46CE-9674-3C059F1FD295Q37741408-4C924EA5-B590-4ED1-A1BB-BEFBBF8653D1Q37855817-4DB639FD-9F4A-4DF9-BFF6-8B12C407E45BQ37941758-FEB322DC-91AA-4E93-9A36-068E01C06B68Q38055067-A2AA1CB9-FA60-4397-87E4-87B4F2E49BB5Q38205719-4D5CD631-28B4-46FD-AFBC-A59BC35E1689Q38234908-93537E9F-AD10-4A59-A968-C58B29AF0CB1Q38868735-4CA3F8CD-97F9-49F8-B021-632A9A08482EQ38959358-577D044D-6A91-4F49-B76A-08874C8C5451Q39051270-2EC90D5E-1AC8-4006-B104-3C66DD900964Q39152151-5379C522-4B96-4C44-B88E-7390A647E86FQ39547831-497F6604-E8C6-4E77-8EE2-9CA99A3666DAQ47093736-1051C290-3AE1-45F7-B9CA-5A38827BC25BQ49843204-ED0E5365-54A9-444A-B301-1015B29A5A4AQ51009755-1B1E45ED-A178-43A9-BA15-B405A63FBF76Q51039534-3975D7E4-0759-4888-8ACA-E46FD03A36EEQ51170112-A9812417-209C-4118-9720-DD27267DE3FCQ52675650-BBBFFC14-0EB9-43BF-A77A-5DC1CCC4CE87
P2860
Inhibition of P-glycoprotein (ABCB1)- and multidrug resistance-associated protein 1 (ABCC1)-mediated transport by the orally administered inhibitor, CBT-1((R)).
description
2007 nî lūn-bûn
@nan
2007 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Inhibition of P-glycoprotein ( ...... istered inhibitor, CBT-1((R)).
@ast
Inhibition of P-glycoprotein ( ...... istered inhibitor, CBT-1((R)).
@en
Inhibition of P-glycoprotein ( ...... istered inhibitor, CBT-1((R)).
@nl
type
label
Inhibition of P-glycoprotein ( ...... istered inhibitor, CBT-1((R)).
@ast
Inhibition of P-glycoprotein ( ...... istered inhibitor, CBT-1((R)).
@en
Inhibition of P-glycoprotein ( ...... istered inhibitor, CBT-1((R)).
@nl
prefLabel
Inhibition of P-glycoprotein ( ...... istered inhibitor, CBT-1((R)).
@ast
Inhibition of P-glycoprotein ( ...... istered inhibitor, CBT-1((R)).
@en
Inhibition of P-glycoprotein ( ...... istered inhibitor, CBT-1((R)).
@nl
P2093
P2860
P1476
Inhibition of P-glycoprotein ( ...... nistered inhibitor, CBT-1((R))
@en
P2093
Daryl Barnett
Elizabeth M Finley
Robert K Oldham
Suneet Shukla
Suresh V Ambudkar
Susan E Bates
P2860
P304
P356
10.1016/J.BCP.2007.12.001
P407
P50
P577
2007-12-14T00:00:00Z